Samsung Bioepis’ latest US biosimilar market report

11 October 2024

South Korea’s Samsung Bioepis has released its Fourth Quarter 2024 Biosimilar Market Report, marking the seventh-edition of the Quarterly Biosimilar Market Report in the United States.

The report provides the latest insights into the US biosimilar landscape, including updated Average Sales Price (ASP) and Wholesales Acquisition Cost (WAC) information across 11 molecules, including the newly launched tocilizumab biosimilars. In this report’s Biosimilar Deep Dive section, it features a survey from 20 payers and pharmacy benefit managers (PBMs) which highlights different biosimilar adoption strategies that payers and PBMs have implemented for each line of business (LOB; Commercial, Medicaid, and Medicare) and what can be done to further optimize biosimilar benefits.

“In this report, we explore the potential savings for stakeholders through the adoption of biosimilars, examine the varying challenges by line of business, and discuss strategies that can maximize these benefits,” said Thomas Newcomer, Vice President, Head of Market Access, US, at Samsung Bioepis. “Biosimilars have already contributed an estimated $36 billion in savings to the US healthcare market, but there is still significant room for growth. Our hope is that stakeholders will become more familiar with biosimilars and continue to embrace their potential.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars